Report : Europe Pharma ADMET Testing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Testing Type (In Vivo ADMET Testing, In Vitro ADMET Testing, and In Silico ADMET Testing), Technology (Cell Culture, High Throughput, Molecular Imaging, and OMICS Technology), and Application (Systemic Toxicity, Renal Toxicity, Hepatotoxicity, Neurotoxicity, and Others)
At 10.3% CAGR, the Europe pharma ADMET testing market is speculated to be worth US$ 3,971.68 million by 2028, says Business Market Insights
According to Business Market Insights’ research, the Europe pharma ADMET testing market was valued at US$ 2,199.98 million in 2022 and is expected to reach US$ 3,971.68 million by 2028, registering an annual growth rate of 10.3% from 2022 to 2028. The high rate of late-stage drug failure and automation and advancements in ADME testing are the critical factors attributed to the market expansion.
The disaster of a rising number of therapeutic molecules in the last phases of clinical trials has cost money and valuable time invested in the research and development of new drugs. This has led to higher investments being made in the development of fresher technology for toxicity testing. According to the article “Importance of ADME/Tox in Early Drug Discovery,” 2022, in the current drug discovery and development pipeline, only 10 molecules out of 1,000 screened hits are projected to enter the preclinical testing stage, and only 9.6% will enter clinical trials. The drug approval process is projected to take 15 years on average, and phases II and III are the most expensive phases of clinical trials. According to the study titled “Why 90% of Clinical Drug Development Fails and How to Improve It?”, 2022, 90% of clinical drug development fails despite the successful implementation of many strategies. After entering clinical investigations, 9 out of 10 drug candidates fail during phase I, II, and III clinical trials, and the drug approval process. Drug candidates rejected in preclinical stages are not included in the 90% failure rate of the drugs in clinical stages, as they do not enter the phase I clinical trials. If preclinical drug candidates are included, the failure rate of drug discovery and development rises even higher than 90%. According to analyses of clinical trial data from 2010 to 2017, lacking clinical effectiveness (40–50%), uncontrollable toxicity (30%), poor drug-like qualities (10–15%), no commercial needs, and ineffective strategic planning (10%) are the four major causes of trial failure. New drug development is both resource and time-intensive, where later clinical stages result in significant costs. To lower the attrition rate in drug research & development, it is crucial to filter and optimize the absorption, distribution, metabolism, elimination, and toxicity (ADMET) characteristics of pharmaceuticals at an early stage. It has been widely accepted that drug ADMET properties should be considered as early as possible to reduce failure rates in the clinical phase of drug discovery. In vitro and in vivo drug evaluation techniques have reached maturity in preclinical applications, and in silico technologies are gaining vast acceptance to evaluate the relevant properties of drugs in the preclinical stage. The development of software programs and in silico models is further promoting the implementation of ADMET studies. Thus, the increasing need for ADME testing in drug development boosts the pharma ADMET testing market.
On the contrary, high cost of ADME testing studies hurdles the growth of Europe pharma ADMET testing market.
Based on testing type, the Europe pharma ADMET testing market is segmented into in vivo ADMET testing, in vitro ADMET testing, and in silico ADMET testing. The in vivo ADMET testing segment held 52.0% market share in 2022, amassing US$ 1,143.56 million. It is projected to garner US$ 2,055.96 million by 2028 to expand at 10.3% CAGR during 2022–2028.
Based on technology, the Europe pharma ADMET testing market is segmented into cell culture, high throughput, molecular imaging, and OMICS technology. The cell culture segment held 42.1% market share in 2022, amassing US$ 927.02 million. It is projected to garner US$ 1,685.75 million by 2028 to expand at 10.5% CAGR during 2022–2028.
By the application, the Europe pharma ADMET testing market is fragmented into systemic toxicity, renal toxicity, hepatotoxicity, neurotoxicity, and others. With 66.3% share of the domain, the systemic toxicity segment dominated the market in 2022. It accrued US$ 1,457.79 million in 2022 and is estimated to generate US$ 2,648.81 million by 2028 to grow at a CAGR of 10.5% over the forecast period.
Based on country, the Europe pharma ADMET testing market is categorized into Germany, the UK, France, Italy, Spain, and the rest of Europe. Our regional analysis states that the rest of Europe captured 22.4% market share in 2022. It was assessed at US$ 492.42 million in 2022 and is likely to hit US$ 847.98 million by 2028, exhibiting a CAGR of 9.5% during the forecast period.
Key players dominating the Europe pharma ADMET testing market are Agilent Technologies, Inc.; Bio-Rad Laboratories, Inc.; Biovia (Dassault Systèmes); Charles River Laboratories; CMIC HOLDINGS Co., LTD; Cyprotex Limited; IQVIA Inc.; MERCK KGaA; Promega Corporation; and Wuxi AppTec among others.
- In Jan 2017, Evotec AG announced that Cyprotex, a company wholly owned by Evotec AG, has completed the relocation of its UK operations from Macclesfield to Alderley Park. The move will consolidate Cyprotex' UK operations into a single, state-of-the-art facility enabling its continued business growth.
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: firstname.lastname@example.org